144 related articles for article (PubMed ID: 36401148)
1. Genetic Profiling of Diffuse Large B-Cell Lymphoma: A Comparison Between Double-Expressor Lymphoma and Non-Double-Expressor Lymphoma.
Chen H; Qin Y; Liu P; Yang J; Gui L; He X; Zhang C; Zhou S; Zhou L; Yang S; Shi Y
Mol Diagn Ther; 2023 Jan; 27(1):75-86. PubMed ID: 36401148
[TBL] [Abstract][Full Text] [Related]
2. Clinical significance of 'double-hit' and 'double-expression' lymphomas.
Ma Z; Niu J; Cao Y; Pang X; Cui W; Zhang W; Li X
J Clin Pathol; 2020 Mar; 73(3):126-138. PubMed ID: 31615842
[TBL] [Abstract][Full Text] [Related]
3. Prognostic impact of diffuse large B-cell lymphoma with extra copies of MYC, BCL2 and/or BCL6: comparison with double/triple hit lymphoma and double expressor lymphoma.
Huang S; Nong L; Wang W; Liang L; Zheng Y; Liu J; Li D; Li X; Zhang B; Li T
Diagn Pathol; 2019 Jul; 14(1):81. PubMed ID: 31315646
[TBL] [Abstract][Full Text] [Related]
4. Relapsed or Refractory Double-Expressor and Double-Hit Lymphomas Have Inferior Progression-Free Survival After Autologous Stem-Cell Transplantation.
Herrera AF; Mei M; Low L; Kim HT; Griffin GK; Song JY; Merryman RW; Bedell V; Pak C; Sun H; Paris T; Stiller T; Brown JR; Budde LE; Chan WC; Chen R; Davids MS; Freedman AS; Fisher DC; Jacobsen ED; Jacobson CA; LaCasce AS; Murata-Collins J; Nademanee AP; Palmer JM; Pihan GA; Pillai R; Popplewell L; Siddiqi T; Sohani AR; Zain J; Rosen ST; Kwak LW; Weinstock DM; Forman SJ; Weisenburger DD; Kim Y; Rodig SJ; Krishnan A; Armand P
J Clin Oncol; 2017 Jan; 35(1):24-31. PubMed ID: 28034071
[TBL] [Abstract][Full Text] [Related]
5. Upfront autologous hematopoietic stem cell transplantation for high-risk patients with double-expressor diffuse large B cell lymphoma.
Kim YR; Yoon SO; Kim SJ; Cheong JW; Chung H; Lee JY; Jang JE; Kim Y; Yang WI; Min YH; Kim JS
Ann Hematol; 2020 Sep; 99(9):2149-2157. PubMed ID: 32390113
[TBL] [Abstract][Full Text] [Related]
6. Myc rearrangement and concurrent high protein expression of C-Myc/Bcl2 carry an adverse prognosis in diffuse large B-cell lymphoma.
Wang X; He J; He H; Shuai Y; Wang L; Li Y; Huang Y; Yu K; Zhao M; Xie T; Li D
Ann Diagn Pathol; 2023 Oct; 66():152165. PubMed ID: 37348414
[TBL] [Abstract][Full Text] [Related]
7. Clinical Impact of the Cell-of-Origin Classification and the MYC/ BCL2 Dual Expresser Status in Diffuse Large B-Cell Lymphoma Treated Within Prospective Clinical Trials of the German High-Grade Non-Hodgkin's Lymphoma Study Group.
Staiger AM; Ziepert M; Horn H; Scott DW; Barth TFE; Bernd HW; Feller AC; Klapper W; Szczepanowski M; Hummel M; Stein H; Lenze D; Hansmann ML; Hartmann S; Möller P; Cogliatti S; Lenz G; Trümper L; Löffler M; Schmitz N; Pfreundschuh M; Rosenwald A; Ott G;
J Clin Oncol; 2017 Aug; 35(22):2515-2526. PubMed ID: 28525305
[TBL] [Abstract][Full Text] [Related]
8. Negative impact of concurrent overexpression of MYC and BCL2 in patients with advanced diffuse large B-cell lymphoma treated with dose-intensified immunochemotherapy.
Takahashi H; Miura K; Nakagawa M; Sugitani M; Amano Y; Kurita D; Sakagami M; Ohtake S; Uchino Y; Kodaira H; Iriyama N; Kobayashi S; Hojo A; Kobayashi Y; Hirabayashi Y; Kusuda M; Hatta Y; Nakayama T; Takei M
Leuk Lymphoma; 2016 Dec; 57(12):2784-2790. PubMed ID: 27071312
[TBL] [Abstract][Full Text] [Related]
9. Clinicopathologic and genetic features of the starry-sky pattern in double-expressor diffuse large B-cell lymphoma.
Sung HJ; Kim D; Yoon DH; Cho H; Huh J; Suh CW; Go H
Hum Pathol; 2023 Sep; 139():106-116. PubMed ID: 37517597
[TBL] [Abstract][Full Text] [Related]
10. Prognostic value of
Qin Y; Chen H; Liu P; Zhang C; Yang J; Gui L; He X; Zhou L; Zhou S; Jiang S; Jiang H; Shi Y
Cancer Biol Med; 2021 Nov; 19(6):893-909. PubMed ID: 34806851
[TBL] [Abstract][Full Text] [Related]
11. BCL2 super-expressor diffuse large B-cell lymphoma: a distinct subgroup associated with poor prognosis.
Roh J; Cho H; Pak HK; Lee YS; Lee SW; Ryu JS; Chae EJ; Kim KW; Huh J; Choi YS; Jeong SH; Suh C; Yoon DH; Park CS
Mod Pathol; 2022 Apr; 35(4):480-488. PubMed ID: 34764434
[TBL] [Abstract][Full Text] [Related]
12. Dose-adjusted EPOCH and rituximab for the treatment of double expressor and double-hit diffuse large B-cell lymphoma: impact of TP53 mutations on clinical outcome.
Dodero A; Guidetti A; Marino F; Tucci A; Barretta F; Re A; Balzarotti M; Carniti C; Monfrini C; Chiappella A; Cabras A; Facchetti F; Pennisi M; Rahal D; Monti V; Devizzi L; Miceli R; Cocito F; Farina L; Ricci F; Rossi G; Carlo-Stella C; Corradini P
Haematologica; 2022 May; 107(5):1153-1162. PubMed ID: 34289655
[TBL] [Abstract][Full Text] [Related]
13. Double-Expressor Lymphoma Is Associated with Poor Outcomes after Allogeneic Hematopoietic Cell Transplantation.
Kawashima I; Inamoto Y; Maeshima AM; Nomoto J; Tajima K; Honda T; Shichijo T; Kawajiri A; Takemura T; Onishi A; Ito A; Tanaka T; Fuji S; Kurosawa S; Kim SW; Maruyama D; Tobinai K; Kobayashi Y; Fukuda T
Biol Blood Marrow Transplant; 2018 Feb; 24(2):294-300. PubMed ID: 29037890
[TBL] [Abstract][Full Text] [Related]
14. Clinical Significance of
Ting CY; Chang KM; Kuan JW; Sathar J; Chew LP; Wong OJ; Yusuf Y; Wong L; Samsudin AT; Pana MNBM; Lee SK; Gopal NSR; Puri R; Ong TC; Bahari SK; Goh AS; Teoh CS
Int J Med Sci; 2019; 16(4):556-566. PubMed ID: 31171907
[No Abstract] [Full Text] [Related]
15. C-MYC and BCL2: Correlation between Protein Over-Expression and Gene Translocation and Impact on Outcome in Diffuse Large B Cell Lymphoma.
Mohammed AA; Rashed HE; Abdelrahman AE; Obaya AA; Toam M; Abdel Nour HM; Abdelhamid MI; Elsayed FM
Asian Pac J Cancer Prev; 2019 May; 20(5):1463-1470. PubMed ID: 31127909
[TBL] [Abstract][Full Text] [Related]
16. MYC expression in concert with BCL2 and BCL6 expression predicts outcome in Chinese patients with diffuse large B-cell lymphoma, not otherwise specified.
Yan LX; Liu YH; Luo DL; Zhang F; Cheng Y; Luo XL; Xu J; Cheng J; Zhuang HG
PLoS One; 2014; 9(8):e104068. PubMed ID: 25090026
[TBL] [Abstract][Full Text] [Related]
17. Clinical relevance of MYC/BCL2 expression and cell of origin in patients with diffuse large b-cell lymphoma treated with autologous transplant.
Al-Juhaishi T; Wang Y; Milton DR; Xu-Monette ZY; Jabbour E; Daher M; Im JS; Bashir Q; Iyer SP; Marin D; Olson AL; Popat U; Qazilbash M; Rondon G; Gulbis AM; Champlin RE; Young KH; Khouri IF
Bone Marrow Transplant; 2023 Sep; 58(9):1000-1007. PubMed ID: 37198234
[TBL] [Abstract][Full Text] [Related]
18. Patterns of Failure in Patients With Double Hit or Double Expressor Lymphomas: Implications for Radiation Therapy.
Tumati V; Trivedi L; Li HC; Patel P; Scaglioni PP; Vusirikala M; Sadeghi N; Rizvi S; Chen W; Wachsmann J; Collins R; Desai NB
Int J Radiat Oncol Biol Phys; 2018 Apr; 100(5):1126-1132. PubMed ID: 29722657
[TBL] [Abstract][Full Text] [Related]
19. [Prognostic evaluation of P53 and BCL2 proteins in MYC/BCL2 double expression DLBCL].
Huang P; Chen S; Yang X; Lei YY; Xu XY; Liu YX; Guo YH; Pan Y; Wang XH; Zhang HL; Fu K; Meng B
Zhonghua Xue Ye Xue Za Zhi; 2019 Jul; 40(7):589-593. PubMed ID: 32397023
[No Abstract] [Full Text] [Related]
20. The Spectrum of MYC Alterations in Diffuse Large B-Cell Lymphoma.
Xia Y; Zhang X
Acta Haematol; 2020; 143(6):520-528. PubMed ID: 32074595
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
